Avenue Therapeutics (NASDAQ:ATXI) announced its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06), Fidelity Earnings reports.
Shares of NASDAQ:ATXI traded down $0.07 on Thursday, reaching $6.00. The company’s stock had a trading volume of 300 shares, compared to its average volume of 171,897. Avenue Therapeutics has a 52-week low of $2.85 and a 52-week high of $12.34. The stock has a market capitalization of $100.49 million, a P/E ratio of -10.53 and a beta of 0.71. The stock’s 50-day moving average is $6.02 and its two-hundred day moving average is $5.96.
Several analysts have recently weighed in on ATXI shares. Zacks Investment Research raised Avenue Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 12th. HC Wainwright reiterated a “hold” rating and issued a $6.00 price objective on shares of Avenue Therapeutics in a research note on Friday, December 18th.
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
See Also: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.